- Home
- RPAY vs ETON Comparison
RPAY vs ETON Comparison
Compare RPAY & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- ETON
- Stock Information
- Founded
- RPAY 2006
- ETON 2017
- Country
- RPAY United States
- ETON United States
- Employees
- RPAY N/A
- ETON N/A
- Industry
- RPAY Business Services
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- ETON Health Care
- Exchange
- RPAY Nasdaq
- ETON Nasdaq
- Market Cap
- RPAY 387.2M
- ETON 388.3M
- IPO Year
- RPAY N/A
- ETON 2018
- Fundamental
- Price
- RPAY $4.79
- ETON $14.85
- Analyst Decision
- RPAY Buy
- ETON Strong Buy
- Analyst Count
- RPAY 9
- ETON 3
- Target Price
- RPAY $8.06
- ETON $29.67
- AVG Volume (30 Days)
- RPAY 1.3M
- ETON 621.3K
- Earning Date
- RPAY 08-07-2025
- ETON 08-07-2025
- Dividend Yield
- RPAY N/A
- ETON N/A
- EPS Growth
- RPAY N/A
- ETON N/A
- EPS
- RPAY N/A
- ETON N/A
- Revenue
- RPAY $309,647,000.00
- ETON $48,327,000.00
- Revenue This Year
- RPAY N/A
- ETON $103.21
- Revenue Next Year
- RPAY $8.40
- ETON $51.34
- P/E Ratio
- RPAY N/A
- ETON N/A
- Revenue Growth
- RPAY 2.26
- ETON 40.88
- 52 Week Low
- RPAY $3.59
- ETON $3.25
- 52 Week High
- RPAY $10.16
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- RPAY 48.67
- ETON 54.31
- Support Level
- RPAY $4.84
- ETON $13.78
- Resistance Level
- RPAY $5.12
- ETON $16.27
- Average True Range (ATR)
- RPAY 0.16
- ETON 0.83
- MACD
- RPAY -0.00
- ETON 0.32
- Stochastic Oscillator
- RPAY 42.61
- ETON 77.67
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.